Cargando…

Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy

IMPORTANCE: Antithrombotic treatment after myocardial infarction (MI) should be individualized based on the patient’s risk of ischemic and bleeding events. Uncertainty remains regarding the relative prognostic importance of the 2 types of events, and further study would be useful. OBJECTIVES: To com...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonsson, Moa, Alfredsson, Joakim, Szummer, Karolina, Jernberg, Tomas, Ueda, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425148/
https://www.ncbi.nlm.nih.gov/pubmed/36036452
http://dx.doi.org/10.1001/jamanetworkopen.2022.20030
_version_ 1784778385290952704
author Simonsson, Moa
Alfredsson, Joakim
Szummer, Karolina
Jernberg, Tomas
Ueda, Peter
author_facet Simonsson, Moa
Alfredsson, Joakim
Szummer, Karolina
Jernberg, Tomas
Ueda, Peter
author_sort Simonsson, Moa
collection PubMed
description IMPORTANCE: Antithrombotic treatment after myocardial infarction (MI) should be individualized based on the patient’s risk of ischemic and bleeding events. Uncertainty remains regarding the relative prognostic importance of the 2 types of events, and further study would be useful. OBJECTIVES: To compare the association of ischemic vs bleeding events with mortality in patients with a recent MI and assess whether the relative mortality risk for the 2 types of events has changed over the past 2 decades. DESIGN, SETTING, AND PARTICIPANTS: A cohort study based on nationwide registers in Sweden, 2012-2017, was conducted. Data were analyzed between July 2021 and May 2022. Patients with MI who were discharged alive with antithrombotic therapy (antiplatelet therapy or oral anticoagulation) were included in the analysis. MAIN OUTCOMES AND MEASURES: The incidence of a first ischemic event (hospitalization for MI or ischemic stroke) or bleeding event (hospitalization with bleeding) up to 1 year after discharge and the mortality risk up to 1 year after each type of event were assessed. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs) for 1-year mortality after an ischemic and bleeding event vs no event, and after an ischemic vs bleeding event. Adjusted HRs for mortality after ischemic vs bleeding events were compared among patients discharged in 1997-2000, 2001-2011, and 2012-2017. RESULTS: Of 86 736 patients discharged after MI in 2012-2017 (median age, 71 [IQR, 62-80] years; 57 287 [66.0%] men), 4039 individuals experienced a first ischemic event (5.7 per 100 person-years) and 3399 experienced a first bleeding event (4.8 per 100 person-years). The mortality rate was 46.2 per 100 person-years after an ischemic event and 27.1 per 100 person-years after a bleeding event. The aHR for 1-year mortality vs no event was 4.16 (95% CI, 3.91-4.43) after an ischemic event and 3.43 (95% CI, 3.17-3.71) after a bleeding event. When the 2 types of events were compared, the aHR was 1.27 (95% CI, 1.15-1.40) for an ischemic vs bleeding event. There was no statistically significant difference in the aHR of an ischemic vs bleeding event in 1997-2000, 2001-2011, and 2012-2017. CONCLUSIONS AND RELEVANCE: In this nationwide cohort study of patients with a recent MI, postdischarge ischemic events were more common and associated with higher mortality risk compared with bleeding events.
format Online
Article
Text
id pubmed-9425148
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-94251482022-09-16 Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy Simonsson, Moa Alfredsson, Joakim Szummer, Karolina Jernberg, Tomas Ueda, Peter JAMA Netw Open Original Investigation IMPORTANCE: Antithrombotic treatment after myocardial infarction (MI) should be individualized based on the patient’s risk of ischemic and bleeding events. Uncertainty remains regarding the relative prognostic importance of the 2 types of events, and further study would be useful. OBJECTIVES: To compare the association of ischemic vs bleeding events with mortality in patients with a recent MI and assess whether the relative mortality risk for the 2 types of events has changed over the past 2 decades. DESIGN, SETTING, AND PARTICIPANTS: A cohort study based on nationwide registers in Sweden, 2012-2017, was conducted. Data were analyzed between July 2021 and May 2022. Patients with MI who were discharged alive with antithrombotic therapy (antiplatelet therapy or oral anticoagulation) were included in the analysis. MAIN OUTCOMES AND MEASURES: The incidence of a first ischemic event (hospitalization for MI or ischemic stroke) or bleeding event (hospitalization with bleeding) up to 1 year after discharge and the mortality risk up to 1 year after each type of event were assessed. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs) for 1-year mortality after an ischemic and bleeding event vs no event, and after an ischemic vs bleeding event. Adjusted HRs for mortality after ischemic vs bleeding events were compared among patients discharged in 1997-2000, 2001-2011, and 2012-2017. RESULTS: Of 86 736 patients discharged after MI in 2012-2017 (median age, 71 [IQR, 62-80] years; 57 287 [66.0%] men), 4039 individuals experienced a first ischemic event (5.7 per 100 person-years) and 3399 experienced a first bleeding event (4.8 per 100 person-years). The mortality rate was 46.2 per 100 person-years after an ischemic event and 27.1 per 100 person-years after a bleeding event. The aHR for 1-year mortality vs no event was 4.16 (95% CI, 3.91-4.43) after an ischemic event and 3.43 (95% CI, 3.17-3.71) after a bleeding event. When the 2 types of events were compared, the aHR was 1.27 (95% CI, 1.15-1.40) for an ischemic vs bleeding event. There was no statistically significant difference in the aHR of an ischemic vs bleeding event in 1997-2000, 2001-2011, and 2012-2017. CONCLUSIONS AND RELEVANCE: In this nationwide cohort study of patients with a recent MI, postdischarge ischemic events were more common and associated with higher mortality risk compared with bleeding events. American Medical Association 2022-08-29 /pmc/articles/PMC9425148/ /pubmed/36036452 http://dx.doi.org/10.1001/jamanetworkopen.2022.20030 Text en Copyright 2022 Simonsson M et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Simonsson, Moa
Alfredsson, Joakim
Szummer, Karolina
Jernberg, Tomas
Ueda, Peter
Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
title Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
title_full Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
title_fullStr Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
title_full_unstemmed Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
title_short Association of Ischemic and Bleeding Events With Mortality Among Patients in Sweden With Recent Acute Myocardial Infarction Receiving Antithrombotic Therapy
title_sort association of ischemic and bleeding events with mortality among patients in sweden with recent acute myocardial infarction receiving antithrombotic therapy
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425148/
https://www.ncbi.nlm.nih.gov/pubmed/36036452
http://dx.doi.org/10.1001/jamanetworkopen.2022.20030
work_keys_str_mv AT simonssonmoa associationofischemicandbleedingeventswithmortalityamongpatientsinswedenwithrecentacutemyocardialinfarctionreceivingantithrombotictherapy
AT alfredssonjoakim associationofischemicandbleedingeventswithmortalityamongpatientsinswedenwithrecentacutemyocardialinfarctionreceivingantithrombotictherapy
AT szummerkarolina associationofischemicandbleedingeventswithmortalityamongpatientsinswedenwithrecentacutemyocardialinfarctionreceivingantithrombotictherapy
AT jernbergtomas associationofischemicandbleedingeventswithmortalityamongpatientsinswedenwithrecentacutemyocardialinfarctionreceivingantithrombotictherapy
AT uedapeter associationofischemicandbleedingeventswithmortalityamongpatientsinswedenwithrecentacutemyocardialinfarctionreceivingantithrombotictherapy